Latest & greatest articles for copd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd

181. Resilience as a concept for understanding family caregiving of adults with Chronic Obstructive Pulmonary Disease (COPD): an integrative review (Full text)

Resilience as a concept for understanding family caregiving of adults with Chronic Obstructive Pulmonary Disease (COPD): an integrative review This paper was a report of the synthesis of evidence on examining the origins and definitions of the concept of resilience, investigating its application in chronic illness management and exploring its utility as a means of understanding family caregiving of adults with Chronic Obstructive Pulmonary Disease.Resilience is a concept that is becoming (...) relevant to understanding how individuals and families live with illness, especially long-term conditions. Caregivers of adults with Chronic Obstructive Pulmonary Disease must be able to respond to exacerbations of the condition and may themselves experience cognitive imbalances. Yet, resilience as a way of understanding family caregiving of adults with COPD is little explored.Literature review - integrative review.CINAHL, PubMed, Google Scholar and EBSCO were searched between 1989-2015.The principles

2016 Nursing open PubMed

182. Oxygen-Induced Hypercapnia in COPD: What is the Mechanism?

Oxygen-Induced Hypercapnia in COPD: What is the Mechanism? Oxygen-Induced Hypercapnia in COPD: What is the Mechanism? – Clinical Correlations Search Oxygen-Induced Hypercapnia in COPD: What is the Mechanism? September 28, 2016 5 min read By Jonathan Glatt Peer Reviewed It was my first week on the wards as a third-year medical student, and I found myself huddled with the team in a busy corner of the Bellevue ED, listening to a man cough and wheeze his way through an interview. He was an elderly (...) patient with an extensive smoking history–a lifetime of a destructive habit that had dilated and distorted his lungs beyond repair. He told us, between bouts of breathlessness, of worsening dyspnea and copious sputum production over the past couple of days, riding into his diseased alveoli on the viral coattails of a recent upper respiratory infection. Armed with a presumptive diagnosis of acute chronic obstructive pulmonary disease (COPD) exacerbation, we proceeded to manage his symptoms in full

2016 Clinical Correlations

183. Sleep quality disturbances and cognitive functioning in elderly patients with COPD (Full text)

Sleep quality disturbances and cognitive functioning in elderly patients with COPD Information about the association between cognitive functions, such as copying function, and sleep disturbances in patients with chronic obstructive pulmonary disease (COPD) is lacking. This cross-sectional observational study aimed to investigate the association between copying function and self-reported sleep quality disturbances and disease severity in an elderly COPD population. Cognitive function (...) performances, assessed using the Mini-Mental State Examination, were compared in 562 ambulatory COPD patients with and without sleep disturbances; assessed using the Established Populations for Epidemiologic Studies of the Elderly questionnaire; and stratified by Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades. Sleep disturbances overall were not correlated with cognitive functioning. A trend was revealed towards worse design copying in patients with sleep disturbances overall. GOLD I

2016 ERJ open research PubMed

184. Prevalence of Osteoporosis and Its Risk Factors in Men with COPD in Qazvin (Full text)

Prevalence of Osteoporosis and Its Risk Factors in Men with COPD in Qazvin Introduction. Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. Proper diagnosis of osteoporosis as a systemic adverse effect of COPD is of significant importance. The present study aimed at evaluating the prevalence of osteoporosis and its risk factors in men suffering from COPD in Qazvin (2014). Methods. This descriptive-analytical study was conducted on 90 patients (...) with COPD using random sampling. Anthropometric data and results from physical examination were collected. Pulmonary function test and bone mineral densitometry were done for all participants as well. Results. The prevalence of osteopenia and osteoporosis in COPD patients was 31.5 and 52.8 percent, respectively. Bone mineral density (BMD) at the femoral neck was associated significantly with body mass index (BMI), increased severity of COPD, and use of oral corticosteroid (P < 0.05). Conclusion

2016 International journal of chronic diseases PubMed

185. Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice. (Full text)

Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice. Evidence for the management of chronic obstructive pulmonary disease (COPD) comes from closely monitored efficacy trials involving groups of patients who were selected on the basis of restricted entry criteria. There is a need for randomized trials to be conducted in conditions that are closer to usual clinical practice.In a controlled effectiveness trial conducted in 75 general practices, we randomly assigned 2799 (...) patients with COPD to a once-daily inhaled combination of fluticasone furoate at a dose of 100 μg and vilanterol at a dose of 25 μg (the fluticasone furoate-vilanterol group) or to usual care (the usual-care group). The primary outcome was the rate of moderate or severe exacerbations among patients who had had an exacerbation within 1 year before the trial. Secondary outcomes were the rates of primary care contact (contact with a general practitioner, nurse, or other health care professional

2016 NEJM PubMed

186. A validation of the National Early Warning Score to predict outcome in patients with COPD exacerbation (PubMed)

A validation of the National Early Warning Score to predict outcome in patients with COPD exacerbation The National Early Warning Score (NEWS), proposed as a standardised track and trigger system, may perform less well in acute exacerbation of COPD (AECOPD). This study externally validated NEWS and modifications (Chronic Respiratory Early Warning Score (CREWS) and Salford-NEWS) in AECOPD.An observational cohort study (2012-2014, two UK acute medical units (AMUs)), compared AECOPD (2361

2016 EvidenceUpdates

187. Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD. (Full text)

Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD. Bronchodilators are a central component for treating exacerbations of chronic obstructive pulmonary disease (COPD) all over the world. Clinicians often use nebulisers as a mode of delivery, especially in the acute setting, and many patients seem to benefit from them. However, evidence supporting this choice from systematic analysis is sparse, and available data are frequently biased by the inclusion (...) searched the Cochrane Airways Group Trial Register and reference lists of articles up to 1 July 2016.RCTs of both parallel and cross-over designs. We included RCTs during COPD exacerbations, whether measured during hospitalisation or in an outpatient setting. We excluded RCTs involving mechanically ventilated patients due to the different condition of both patients and airways in this setting.Two review authors independently assessed studies for inclusion, extracted data and assessed the risk of bias

2016 Cochrane PubMed

188. Umeclidinium bromide/Vilanterol. Anoro for COPD. No additions to efficacy just to price

Umeclidinium bromide/Vilanterol. Anoro for COPD. No additions to efficacy just to price 2015. DAR No 6: Umeclidinium bromide/Vilanterol. Anoro® for COPD - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DAR No 6: Umeclidinium bromide/Vilanterol. Anoro® for COPD DAR No 6: Umeclidinium bromide/Vilanterol. Anoro® for COPD Content tools Share it No additions to efficacy, just to price Umeclidinium/vilanterol is a combination of a muscarinic

2016 Drug and Therapeutics Bulletin of Navarre (Spain)

189. Umeclidinium bromide. Incruse for COPD. Very little efficacy

Umeclidinium bromide. Incruse for COPD. Very little efficacy 2015. DAR No 5: Umeclidinium bromide. Incruse® for COPD - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DAR No 5: Umeclidinium bromide. Incruse® for COPD DAR No 5: Umeclidinium bromide. Incruse® for COPD Content tools Share it Very little efficacy Umeclidinium is a long acting muscarinic antagonist (LAMA) authorized for symptom relief in patients with Chronic Obstructive Pulmonary (...) Disease (COPD). They are no comparative data available with tiotropium, or with other LAMA or LABA. It has not shown to reduce the number of exacerbations. Neither does it improve quality of life or reduce the need for rescue treatment in studies lasting more than 12 weeks. There is concern on safety regarding its cardiovascular profile and the possible higher risk of pneumonia. Enviar comentario You can send us a comment or suggestion and we will respond to most frequently asked questions Competing

2016 Drug and Therapeutics Bulletin of Navarre (Spain)

190. Prognostic assessment in COPD without lung function: the B-AE-D indices (Full text)

Prognostic assessment in COPD without lung function: the B-AE-D indices Several composite markers have been proposed for risk assessment in chronic obstructive pulmonary disease (COPD). However, choice of parameters and score complexity restrict clinical applicability. Our aim was to provide and validate a simplified COPD risk index independent of lung function.The PROMISE study (n=530) was used to develop a novel prognostic index. Index performance was assessed regarding 2-year COPD-related (...) mortality and all-cause mortality. External validity was tested in stable and exacerbated COPD patients in the ProCOLD, COCOMICS and COMIC cohorts (total n=2988).Using a mixed clinical and statistical approach, body mass index (B), severe acute exacerbations of COPD frequency (AE), modified Medical Research Council dyspnoea severity (D) and copeptin (C) were identified as the most suitable simplified marker combination. 0, 1 or 2 points were assigned to each parameter and totalled to B-AE-D or B-AE-D-C

2016 EvidenceUpdates PubMed

191. The inflammasome pathway in stable COPD and acute exacerbations (Full text)

The inflammasome pathway in stable COPD and acute exacerbations Chronic obstructive pulmonary disease (COPD) is characterised by pulmonary and systemic inflammation that bursts during exacerbations of the disease (ECOPD). The NLRP3 inflammasome is a key regulatory molecule of the inflammatory response. Its role in COPD is unclear. We investigated the NLRP3 inflammasome status in: 1) lung tissue samples from 38 patients with stable COPD, 15 smokers with normal spirometry and 14 never-smokers (...) ; and 2) sputum and plasma samples from 56 ECOPD patients, of whom 41 could be reassessed at clinical recovery. We observed that: 1) in lung tissue samples of stable COPD patients, NLRP3 and interleukin (IL)-1β mRNA were upregulated, but both caspase-1 and ASC were mostly in inactive form, and 2) during infectious ECOPD, caspase-1, oligomeric ASC and associated cytokines (IL-1β, IL-18) were significantly increased in sputum compared with clinical recovery. The NLRP3 inflammasome is primed

2016 ERJ open research PubMed

192. Only severe COPD is associated with being underweight: results from a population survey (Full text)

Only severe COPD is associated with being underweight: results from a population survey Low body mass index (BMI) and malnutrition in chronic obstructive pulmonary disease (COPD) are associated with a poor prognosis. The prevalence of underweight, as well as overweight, in severity grades of COPD is sparsely investigated in studies of the general population and the associated patterns of risk factors are not well established. The aim of the present study was to determine the association between (...) severity grades of airflow limitation in COPD, and both underweight and obesity when corrected for possible confounding factors. The study is based on pooled data from the OLIN (Obstructive Lung Disease in Northern Sweden) studies. Complete records with lung function, BMI and structured interview data were available from 3942 subjects (50.7% women and 49.3% men). COPD and severity grading were defined using the Global Initiative for Chronic Obstructive Lung Disease criteria. In sensitivity analyses

2016 ERJ open research PubMed

193. Inflammatory bowel disease and risk of mortality in COPD (Full text)

Inflammatory bowel disease and risk of mortality in COPD Patients with chronic obstructive pulmonary disease (COPD) have higher incidence and prevalence of other chronic inflammatory diseases, including inflammatory bowel disease (IBD). We assessed whether IBD onset increases mortality risk in patients with COPD or asthma-associated COPD.Two population-based cohorts of COPD and asthma-COPD subjects were identified using the administrative health databases in Québec, Canada, 1990-2007. Death (...) records were retrieved from the death certificate registry. Cox proportional hazards models were used to assess the impact of newly developed IBD on mortality risk.The COPD and asthma-COPD cohorts included 273 208 and 26 575 patients, respectively, of which 697 and 119 developed IBD. IBD increased the risk of all-cause mortality in both COPD (hazard ratio 1.23, 95% CI 1.09-1.4) and asthma-COPD (hazard ratio 1.65, 95% CI 1.23-2.22). In asthma-COPD patients, IBD increased the risk of mortality from

2016 EvidenceUpdates PubMed

194. Functional characterisation of bone marrow-derived mesenchymal stromal cells from COPD patients (Full text)

Functional characterisation of bone marrow-derived mesenchymal stromal cells from COPD patients Autologous bone marrow-derived mesenchymal stromal cells (BM-MSCs) are evaluated for clinical use in chronic obstructive pulmonary disease (COPD) patients, but it is unclear whether COPD affects BM-MSCs. To investigate this, BM-MSCs from nine COPD patients and nine non-COPD age-matched controls were compared with regard to immunophenotype, growth and differentiation potential, and migration capacity (...) . Other functional assays included the response to pro-inflammatory stimuli and inducers of the nuclear factor (erythroid derived 2)-like 2 antioxidant response element (Nrf2-ARE) pathway, and effects on NCI-H292 airway epithelial cells. No significant differences were observed in terms of morphology, proliferation and migration, except for increased adipocyte differentiation potential in the COPD group. Both groups were comparable regarding mRNA expression of growth factors and inflammatory mediators

2016 ERJ open research PubMed

195. Tai Chi for chronic obstructive pulmonary disease (COPD). (Full text)

Tai Chi for chronic obstructive pulmonary disease (COPD). Tai Chi, a systematic callisthenic exercise first developed in ancient China, involves a series of slow and rhythmic circular motions. It emphasises use of 'mind' or concentration to control breathing and circular body motions to facilitate flow of internal energy (i.e. 'qi') within the body. Normal flow of 'qi' is believed to be essential to sustain body homeostasis, ultimately leading to longevity. The effect of Tai Chi on balance (...) and muscle strength in the elderly population has been reported; however, the effect of Tai Chi on dyspnoea, exercise capacity, pulmonary function and psychosocial status among people with chronic obstructive pulmonary disease (COPD) remains unclear.• To explore the effectiveness of Tai Chi in reducing dyspnoea and improving exercise capacity in people with COPD.• To determine the influence of Tai Chi on physiological and psychosocial functions among people with COPD.We searched the Cochrane Airways

2016 Cochrane PubMed

196. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. (Full text)

Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice treatment for patients with chronic obstructive pulmonary disease (COPD) who have a high risk of exacerbations. The role of treatment with a LABA-LAMA regimen in these patients is unclear.We conducted a 52-week, randomized, double-blind, double-dummy, noninferiority (...) trial. Patients who had COPD with a history of at least one exacerbation during the previous year were randomly assigned to receive, by inhalation, either the LABA indacaterol (110 μg) plus the LAMA glycopyrronium (50 μg) once daily or the LABA salmeterol (50 μg) plus the inhaled glucocorticoid fluticasone (500 μg) twice daily. The primary outcome was the annual rate of all COPD exacerbations.A total of 1680 patients were assigned to the indacaterol-glycopyrronium group, and 1682 to the salmeterol

2016 NEJM PubMed

197. Another Choice for Prevention of COPD Exacerbations. (PubMed)

Another Choice for Prevention of COPD Exacerbations. 27181835 2016 06 21 2018 12 02 1533-4406 374 23 2016 Jun 09 The New England journal of medicine N. Engl. J. Med. Another Choice for Prevention of COPD Exacerbations. 2284-6 10.1056/NEJMe1604444 Donohue James F JF From the Division of Pulmonary Diseases and Critical Care Medicine, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill. eng Editorial Comment 2016 05 15 United States N Engl J Med 0255562 0028-4793 0

2016 NEJM

198. Smoking, Not COPD, as the Disease. (PubMed)

Smoking, Not COPD, as the Disease. 27168438 2016 05 16 2018 12 02 1533-4406 374 19 2016 May 12 The New England journal of medicine N. Engl. J. Med. Smoking, Not COPD, as the Disease. 1885-6 10.1056/NEJMe1515508 Fabbri Leonardo M LM From Dipartimento di Medicina Metabolica, Nuovo Ospedale Civile Sant'Agostino Estense, Azienda Unitá Sanitaria Locale di Modena, Azienda Ospedaliero-Universitaria Policlinico di Modena, Università degli Studi di Modena e Reggio Emilia, Modena, Italy. eng Editorial

2016 NEJM

199. Increasing burden of COPD in rural India: an example why India warrants primary healthcare reforms (Full text)

Increasing burden of COPD in rural India: an example why India warrants primary healthcare reforms Battle against COPD: time to reinforce the primary healthcare units of rural areas of India to combat lung diseases http://ow.ly/ZAwge.

2016 ERJ open research PubMed

200. Measurement duration impacts variability but not impedance measured by the forced oscillation technique in healthy, asthma and COPD subjects (Full text)

Measurement duration impacts variability but not impedance measured by the forced oscillation technique in healthy, asthma and COPD subjects The forced oscillation technique (FOT) is gaining clinical acceptance, facilitated by more commercial devices and clinical data. However, the effects of variations in testing protocols used in FOT data acquisition are unknown. We describe the effect of duration of data acquisition on FOT results in subjects with asthma, chronic obstructive pulmonary (...) disease (COPD) and healthy controls. FOT data were acquired from 20 healthy, 22 asthmatic and 18 COPD subjects for 60 s in triplicate. The first 16, 30 and 60 s of each measurement were analysed to obtain total, inspiratory and expiratory resistance of respiratory system (Rrs) and respiratory system reactance (Xrs) at 5 and 19 Hz. With increasing duration, there was a decrease in total and expiratory Rrs for healthy controls, total and inspiratory Rrs for asthmatic subjects and magnitude of total

2016 ERJ open research PubMed